This interview of Jake Van Naarden $LLY head of corporate business development, by @angelicapeebles - CNBC’s excellent Pharma reporter, has demonstrated once again just how far-sighted Eli Lilly’s strategy really is and how it helps Eli Lilly to strengthen its dominance in the BioTech and Pharma ecosystem. I was especially interested to learn more about the rationale behind Eli Lilly’s staggering deal-making pace and that there is much more to come M&A-wise. Definitely worth your time! $XBI
@pakkbuilderd@ThierryBorgeat 💯
It may require tech to crash.. your points are good, I do not understand it either. NOC also gets no respect for their space program. Confident long term still.
@RonDeSantis Absolutely pathetic. Whether democratic or republican, this level of incompetence is indefensible. Also won’t help those who do not trust the system already.
@_OliverVenture I’m crossing my fingers. My skeptical side knows he stated this IND would be approved in 2023 (NOT A TYPO). I hope IPSC doesn’t fall into this pattern, they affirmed guidance of IND before EOY.
@PatternNotes 🔥 Excellent. Having kids, I believe shaping how kids think and reason is a skill that is incredibly important and should be stressed more than just about anything.